RxDoctor Payments Data

Ankur Sandhu, MD

Nephrology · Fredericksburg, VANPI 1285838698

Payments from drug & device makers

$162in general payments, 2019–2025

Across 16 payments — averaging $10.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$66
  • Fresenius USA Marketing, Inc.$45
  • Dexcom, Inc.$21
  • Boehringer Ingelheim$19
  • Kowa Pharmaceuticals America, Inc.$11

What the payments were for

  • Food & beverage$7748%
  • Education$8552%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$162 in reported general payments places this provider in the 15th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$217,751
Medicare patients
501
Services billed
2,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide16$73,790
FarxigaDapagliflozin Propanediol11$12,753
Lanthanum Carbonate12$9,162
Calcitriol181$1,984
Bumetanide62$1,950
Potassium Citrate ErPotassium Citrate12$1,379
Potassium Chloride32$1,278
Eplerenone12$1,179
Hydralazine Hcl46$596
Furosemide50$346
Losartan Potassium38$283
Carvedilol28$221
Amlodipine Besylate50$220
Doxazosin Mesylate17$216
Tamsulosin Hcl13$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$45$73,79016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 298 nephrology providers in Virginia.

Other nephrology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →